Health In Tech, Inc. (HIT) · Nov 6, 2026 · New debt

Health In Tech debt financing adds cash, but dilution risk grows

$3.0M convertible note — $2.85M gross proceeds; 8.75% interest; conversion at $1.5735 per share

Health In Tech’s new debt financing brings in $2.85M of cash, but adds expensive repayment obligations and potential share dilution.

Health In Tech is an AI-enabled InsurTech platform still investing in distribution, technology and product development while trying to convert contracted and pipeline business into recognized revenue. Its latest reported quarter showed revenue down year over year and a swing to a net loss, while the company had already arranged the SEPA financing to support liquidity.

The company gets useful near-term liquidity, but this is funding—not operating progress. The second closing delivered $2.85 million of gross cash against a $3.0 million note. That helps fund the business, but it does not show that demand, revenue conversion or profitability improved.

TermSecond trancheKey comparison
Principal (Promissory Notes)$3.0MFirst tranche: $7.0M
Gross proceeds (Second Closing)$2.85M5% purchase-price discount
Interest rate (Promissory Notes)8.75%18% upon specified defaults
Fixed conversion price (Promissory Notes)$1.5735/shareFloor: $0.204/share
Exchange Cap (SEPA)13,100,378 shares~19.99% of outstanding shares

The financing structure adds a meaningful dilution and repayment overhang. The notes can be repaid through scheduled installments or by selling stock under the SEPA, and the investor can convert at a fixed price subject to ownership, Nasdaq and anti-dilution limits. 〔0〕

The event was largely anticipated, making the incremental signal smaller and mostly balance-sheet related. The SEPA, the first $7.0 million note and the registration statement were already disclosed; the filing mainly confirms that the second tranche closed after the registration became effective. The immediate issue is now whether shareholders approve issuance beyond the 13.1 million-share exchange cap at the November 10 annual meeting. 〔1〕

Bottom line: This keeps Health In Tech funded in the near term, but at a high financial cost and with more potential dilution. Because the second tranche was already part of the disclosed financing plan, it modestly worsens the financing story rather than changing the company’s operating story outright.

What to watch next

Stockholder vote on excess share issuance, November 10

Original filing on SEC EDGAR

More Health In Tech, Inc. news

Health In Tech debt financing adds cash, but dilution risk grows | HIT Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.